1. Primary hypercholesterolemia (type IIa), combined hyperlipidemia (type IIb): Adjuvant to diet when not controlled by diet and exercise
2. Adjuvant to diet or other lipid-lowering therapy (e.g. LDL apheresis) for homozygous familial hypercholesterolemia
3. Delays the progression of atherosclerosis by lowering total cholesterol and LDL-cholesterol to target levels in patients with hypercholesterolemia. 4. Total cholesterol and LDL in pediatric patients aged 10 to 17 years (for women, at least 1 year after menarche) with heterozygous familial hypercholesterolemia who still meet the criteria below despite dieting. -Adjunct to diet to reduce cholesterol and apo-B protein levels
◦ If LDL-cholesterol is still greater than 190 mg/dL (LDL-C > 190 mg/dL)
◦ LDL-cholesterol still exceeds 160 mg/dL (LDL-C > 160 mg/dL), a family history of premature cardiovascular disease, or two or more cardiovascular disease risk factors.
5. Dietary supplement for patients with primary dysbetalipoproteinemia (type III)
6. Reduced risk of cardiovascular disease: There is no clinical evidence of coronary heart disease, but high sensitive C-reactive protein (hsCRP) is 2 mg/day in men over 50 years of age and women over 60 years of age. L or higher in patients with at least one additional cardiovascular disease risk factor (e.g., high blood pressure, low HDL-cholesterol level, smoking, or family history of premature coronary heart disease, etc.)
- Reduced risk of stroke - Reduced risk of myocardial infarction - Reduced risk of arterial revascularization
2) Usage, dosage
5mg~20mg once a day
Please refer to the product manual for detailed usage and dosage.
